Akerna Corp Stock Forecast & Price Prediction 2026-2027
Algorithmic price targets and analysis for KERN based on fundamentals, valuation multiples, and historical data.
Price Target Summary
Technical Outlook
52-Week Range Analysis
Fundamental Analysis
Revenue Growth Projection
Based on +0.0% YoY growth, tapered 20% per year in outer projections.
Valuation vs Peers
Cash Position
Key Metrics
| Current Price | $6.27 |
| Market Cap | $376.3M |
| P/S Ratio | 55.05x |
| Revenue (TTM) | $6.8M |
| Revenue Growth (YoY) | +0.0% |
| Gross Margin | 4.0% |
| Cash on Hand | N/A |
| Total Debt | $5.1M |
| 52W High | $6.27 |
| 52W Low | $6.27 |
Signal Breakdown
- Negative or flat revenue growth
- Healthy gross margins above 40%
- Total debt exceeds cash position
- Trading near 52-week highs
- Elevated P/S ratio relative to sector
Risk Factors
- High debt-to-cash ratio: total debt of $5.1M significantly exceeds cash of $0.
Analyst Summary
Akerna Corp (KERN) is a Ancillary cannabis company with contracting revenue and a market capitalization of $376.3M. Based on trailing revenue of $6.8M and a P/S ratio of 55.05x, the stock trades at a premium relative to the sector median of 2.5x. Our algorithmic base-case price target of $0.28 implies downside of 95.5% from current levels. The overall signal is bearish, as several fundamental metrics are under pressure. Investors should weigh the 1 identified risk factor before making any investment decision.
Frequently Asked Questions
What is the price target for KERN?+
Is KERN a buy right now?+
What is the revenue forecast for Akerna Corp?+
What are the risks of investing in KERN?+
How does KERN valuation compare to the cannabis sector?+
Important Disclaimer
This is not financial advice. Forecasts are algorithmic projections based on historical data and should not be used as the sole basis for investment decisions. Past performance does not guarantee future results. Cannabis stocks carry significant risk including regulatory, market, and operational risks. Always consult with a qualified financial advisor before making investment decisions. Cannabismarketcap does not recommend buying, selling, or holding any security.